Baylor College of Medicine has synthesized activin receptor type-1 (ACVR1; ALK2; ACTR-I) and/or serine/threonine-protein kinase receptor R3 (ACVRL1; ALK1) inhibitors reported to be useful for the treatment of cancer, fibrodysplasia ossificans progressiva (FOP), atherosclerosis and iron deficiency anemia.